Clinical trials located in Europe

Select your disease:

  • CT-EU-00117630

    Study of a New Antibody for Advanced Solid Tumors

    This here clinical trial is testin’ a new drug called RO7247669. It’s a special kind of antibody that targets two proteins on cancer cells, PD-1 and LAG-3. The goal is to see if this new drug can help fight advanced or metastatic solid tumors like melanoma, lung cancer, and esophageal cancer.

    In the first part of the study, they’ll be givin’ different doses of RO7247669 to patients every 2 or 3 weeks through an IV. They’ll be keepin’ a close eye on any side effects or toxicities that might happen. Once they figure out the highest safe dose, they’ll move on to the next part.

    In that second part, they’ll give that highest safe dose to more patients with them specific cancer types. The main things they’ll be lookin’ at are how well the drug works against the tumors, like whether they shrink or stop growin’ for a while. They’ll also keep watchin’ for any side effects over the course of up to 2 years.

    So in a nutshell, this trial aims to find the best and safest dose of this new dual-targeted antibody drug, and see if it can put up a good fight against advanced solid tumors. If you got one of them cancer types and other treatments ain’t workin’, this here trial might be worth considerin’.

    DenmarkSpainUnited Kingdom
  • Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • Spersonalizowana terapia komórkami T (NEO-PTC-01) w leczeniu pacjentów z nieoperacyjnym czerniakiem lub czerniakiem z przerzutami

    This here clinical trial, called NEO-PTC-01, is aimin’ to test out a new kind of treatment for folks with advanced or metastatic melanoma, which is a serious form of skin cancer that has spread to other parts of the body. The treatment involves takin’ some of the patient’s own immune cells, called T cells, and trainin’ ’em up in a lab to recognize and attack the cancer cells. These souped-up T cells are then given back to the patient through an infusion.

    The study is split into two parts. The first part, called the Dose Finding part, will test out two different doses of the NEO-PTC-01 treatment to see which one is safe and well-tolerated. After that, they’ll also look at givin’ the treatment along with some other drugs like interleukin (IL)-2 and programmed cell death protein 1 (u03b1PD-1) therapy, which are meant to help the immune system fight the cancer even better.

    The second part, called the Dose Expansion part, will give the safe dose of NEO-PTC-01 to a larger group of patients to make sure it’s still safe and to get a better idea of how well it works.

    The main thing the researchers will be keepin’ an eye on is how many patients experience any kind of side effects or adverse events, whether they’re mild or serious. They’ll be watchin’ closely for any problems that might crop up and might need to stop the treatment if things get too dicey.

  • Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    United Kingdom
  • Tebentafusp for the treatment of recurrent melanoma

    The study aims to investigate a new treatment for patients with cutaneous melanoma or uveal melanoma after surgery. Researchers want to see if a new drug called tebentafusp can help these patients live longer.

    Tebentafusp is a new drug that has already been studied in patients with advanced melanoma of the skin and uvea. In this study, this medicine will be administered to patients whose disease has relapsed at the molecular level using a special blood test. Patients will receive tebentafusp for up to 6 months as an intravenous infusion once a week and will then be followed for 12 months to check whether the disease has returned.

    United Kingdom
  • Long-term melatonin intake and evaluation of the effect on melanoma patients

    The aim of this study is to test a new treatment for an eye cancer called uveal melanoma. This cancer can spread to other parts of the body, and once it does, it is extremely difficult to treat. Therefore, the aim of this study is to test whether melatonin for 5 years after the initial cancer diagnosis can help prevent or delay the spread of cancer.

    Half of the study participants will take melatonin tablets (20 mg) at bedtime every day for 5 years, and the other half will take nothing. Researchers will monitor both groups closely, checking for any signs of spread of the cancer with regular imaging and blood tests.

  • Study of pembrolizumab in combination with lenvatinib in the treatment of metastatic uveal melanoma

    This study aims to evaluate a new combination of two anticancer drugs: pembrolizumab and lenvatinib in the treatment of metastatic uveal melanoma. The study is divided into two groups of patients – those who have not previously received tebentafusp and those who have already been treated with it. Doctors suspect that the benefits of anticancer drugs in patients with metastatic uveal melanoma may vary depending on prior exposure to Tebentafusp.

    Participants will receive pembrolizumab for up to 35 cycles, as well as lenvatinib, until disease progression or serious side effects occur. The study aims to assess progression-free survival after 27 weeks of treatment. Regular imaging tests, such as MRI of the liver and CT scan of the chest, abdomen and pelvis, will be performed every 9 weeks to monitor your response to treatment. After completion of treatment, patients will be followed to assess overall survival.

  • Infusion of tumor-infiltrating lymphocytes into the liver of melanoma patients with liver metastases

    This is a clinical trial for a new type of treatment — tumor-infiltrating lymphocytes (TIL). This study will test whether this treatment can help fight melanoma that has spread to the liver. Tumor infiltrating lymphocytes (TILs) are immune system cells that accumxulate around and inside the tumor. They can recognize and attack cancer cells, as well as prevent cancer cells from spreading to other organs. Scientists plan to multiply them in the laboratory and then introduce them back into the patient’s body through the main artery supplying the liver.

    Before this, patients will receive a single dose of melphalan chemotherapy to help prepare their body. After lymphocyte infusion (TIL), patients will also receive interleukin-2, a protein that helps lymphocytes do their job better. The goal is to see if this treatment is safe and effective. Doctors will watch closely for any side effects or serious problems that may arise during treatment.

  • Treatment with Bel-Sar for patients with uveal melanoma

    The aim of this clinical trial is to test a new drug called Belzupacap Sarotalocan, or Bel-sar for short, for people with uveal melanoma.

    The main aim of this study is to test whether bel-sar is safe and effective compared to a dummy treatment, which acts as a placebo. The Bel-sar treatment involves injecting the drug (microinjection) into the eye space and then activating it with a special laser.

    The most important thing researchers want to know is how long it takes for the tumor to start growing again after treatment with bel-sar compared with sham treatment. They will closely monitor participants for up to 52 weeks to see how the situation progresses.

    United Kingdom
  • A study comparing the combination of lifileucel plus pembrolizumab with pembrolizumab alone in the treatment of unresectable, advanced melanoma

    The aim of this study is to test a new treatment for people with advanced melanoma, a serious form of skin cancer that has spread to other parts of the body. The new treatment combines two different therapies: lifileucel, made from the patient’s own immune cells called tumor-infiltrating lymphocytes, and pembrolizumab, a type of immunotherapy drug that helps the body’s immune system fight cancer.

    The study will compare the effectiveness and safety of this combination treatment with pembrolizumab alone. Patients who initially received only pembrolizumab and whose cancer worsened will have the option to switch treatment and receive lifileucel monotherapy.

    The main goals of the study are to see whether the combination treatment can improve the objective response rate, which measures how many patients have had their tumors shrink, and progression-free survival, which is how long patients live without their cancer getting worse. To evaluate the results of the study, patients will be followed for up to 5 years.

    To be eligible for this trial, patients must have advanced melanoma that cannot be surgically removed or has spread to other organs. Additionally, patients cannot be previously treated for metastatic disease, although some prior therapies for earlier stages of melanoma are permitted.

  • Study of an experimental drug TL-895 for myelofibrosis or indolent systemic mastocytosis

    This here clinical trial is studying a new experimental drug called TL-895. TL-895 is taken by mouth and works by blocking certain proteins called tyrosine kinases that are involved in causing myelofibrosis and indolent systemic mastocytosis.

    Participants in the study will receive TL-895 orally in varying doses based on their specific group assignment. These doses range from 150 mg to 450 mg, and the administration could be either once or twice daily, continuing in a consistent 28-day cycle. The primary goal of the study is to determine the recommended phase 2 dose (RP2D) for TL-895 in each patient group based on safety and tolerability data. Additionally, the study aims to assess the effectiveness of TL-895 in reducing spleen volume and improving symptoms associated with Myelofibrosis over a 24-week period.

  • Pembrolizumab and electrochemotherapy performed using a cliniporator in the treatment of malignant melanoma

    This study is looking at the use of pembrolizumab (Keytruda) in combination with a treatment called electrochemotherapy (ECT) in people with malignant melanoma. The main goal is to see if combining these two treatments is safe and can improve the effectiveness of the therapy in shrinking tumors, both those on the surface of the skin and those found in the body.

    Electrochemotherapy involves using electrical pulses along with a drug called Bleomycin to kill cancer cells. This is thought to help the immune system better recognize and attack cancer. Pembrolizumab is an immunotherapy drug that inhibits the cells of the immune system that fight cancer. Scientists believe that by combining these two approaches, a better anti-tumor response can be achieved compared to using pembrolizumab alone.

  • Study of darovasertib in patients with uveal melanoma

    This is a study of a new drug called darovasertib (also known as IDE196 or LXS196) in patients with primary choroidal melanoma. Darovasertib is an oral, potent and selective protein kinase C inhibitor that will be used to treat uveal melanoma.

    The aim of this study is to see if darovasertib can help reduce the size of the tumor before local treatment, such as removal of the eyeball or radiation. Patients will receive darovasertib for a maximum of 6 months before local treatment, and then for a further 6 months after local treatment. Doctors will watch to see if the drug helps avoid having to remove the eyeball or reduce the dose of radiation needed to treat the tumor.

    It is important to monitor for any side effects and changes in laboratory tests while taking darovasertib. Doctors will closely monitor the patient’s health throughout the study, which may last up to 3 years.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • Intravenous treatment with ANV419 — a new therapy for patients with advanced melanoma

    The aim of this clinical trial is to test a new combination treatment for advanced melanoma. The treatment involves taking special immune cells called tumor-infiltrating lymphocytes (TILs for short) from a patient’s tumor and growing them in the laboratory. These TILs are then returned to the patient via intravenous infusion along with a new drug called ANV419.

    ANV419 is designed to help TILs grow and multiply even more once they are back in the patient’s body. Researchers predict that these special TIL cells will be able to better recognize and attack cancer cells, helping the patient’s immune system fight melanoma.

    Doctors will closely monitor any side effects patients experience with the new therapy. They will check whether any adverse events occur, and if they do occur, how often they occur and how serious they may be. The entire study will last about a year, with regular follow-up visits to monitor the effectiveness of the treatment and the patient’s well-being.

  • Treatment for Herniated Disc in the Lower Back

    Howdy there, partner! This here clinical trial is aimin’ to test out a new treatment called STA363 for folks sufferin’ from a herniated disc in their lower back, causin’ that darn sciatic nerve pain. The main goal is to see if this treatment is safe an’ if it can help shrink that bulgin’ disc an’ ease up on the pain.

    Here’s the deal: they’ll be injectin’ either STA363 or a placebo (a fake treatment) right into that herniated disc. About two-thirds of the folks will get the real STA363, while one-third will get the placebo. The docs will be keepin’ a close eye on things to make sure there ain’t no nasty side effects or problems.

    They’ll be takin’ pictures of your back with one of them fancy MRI machines before an’ after the treatment to see if the disc an’ herniation shrink up. You’ll also be keepin’ track of your pain levels every day for a week after the treatment.

    The whole shebang will take about 6 months, with check-ups along the way to make sure everythin’ is goin’ smooth. If this STA363 treatment works like they hope, it could be a game-changer for folks like you sufferin’ from that darn back pain.

  • Study of a New Drug for Moderate to Severe Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no real effects.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week or so for the first few months. The doctors won’t know which one you’re gettin’ until later. You’ll also need to keep takin’ any anti-inflammatory medicines and doin’ physical therapy exercises as you normally would.

    The main thing the researchers are lookin’ at is whether secukinumab can better improve your physical shoulder symptoms like pain, weakness, stiffness, and such compared to the placebo. They’ll be askin’ you to rate your symptoms at different points durin’ the 24-week study.

    It’s important to know that you can’t increase your anti-inflammatory medicine doses or get steroid injections durin’ the study, but you can take other pain meds like acetaminophen if needed. The study involves some medical tests too, like MRI scans and X-rays of your shoulder.

    So in a nutshell, this trial aims to find out if secukinumab works better than a placebo at relievin’ the symptoms of rotator cuff tendinopathy when combined with standard treatments like physical therapy and anti-inflammatory drugs. If you’re interested, you’d be closely monitored and get either the new medicine or a placebo for free as part of the study.

    BulgariaCzechiaDenmarkFrancePortugalSlovakiaUnited Kingdom
  • Study on Secukinumab for Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no active ingredients.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week for the first month, and then once a month after that for another couple of months. The doctors will be keepin’ a close eye on your shoulder symptoms like pain, weakness, stiffness, and any mechanical issues you might be havin’.

    The main thing they’ll be lookin’ at is how much your physical shoulder symptoms improve after 16 weeks of treatment with secukinumab compared to the placebo. They’ll be usin’ a special questionnaire called the Western Ontario Rotator Cuff Index to measure them symptoms.

    Now, durin’ the trial, you’ll need to keep takin’ any anti-inflammatory medicines you’re already on, and keep up with your physical therapy exercises too. But you won’t be allowed to get no steroid injections or increase your medicine doses without the doctors’ say-so.

    After the 16 weeks of treatment, there’ll be another 8 weeks where the doctors will check if the effects of the medicine are lastin’. So in total, you’d be in the study for around 6 months if you join up.

  • Clinical Trial for Finding the Best Dose of Clodronate for Painful Knee Osteoarthritis

    Howdy there, folks! This here clinical trial is aimin’ to find the best dose of a medicine called clodronate for treatin’ painful knee arthritis. It’s gonna be split into two parts.

    In the first part, they’ll have four groups of folks with knee arthritis. Three of them groups will get different doses of clodronate injected right into their knee once a week for four weeks. The fourth group will get a placebo, which is like a fake medicine. They’ll be keepin’ an eye on how safe and tolerable them different doses are.

    Once they figure out which dose works best without too many side effects, they’ll move on to the second part. In that part, they’ll have two groups – one gettin’ the best dose of clodronate from the first part, and the other gettin’ a placebo again. They’ll be checkin’ to see how effective and safe that best dose really is for helpin’ with knee arthritis pain.

    The main thing they’re lookin’ for is if the clodronate can reduce knee pain by at least 10 millimeters on a special pain scale called the Visual Analogue Scale, compared to the placebo group. They’ll be measurin’ that around 7 weeks into the study.

    So in a nutshell, they’re tryin’ to find the best and safest dose of clodronate for helpin’ folks with painful knee arthritis. It’s a two-part study, and they’ll be keepin’ a close eye on how well it works and how well it’s tolerated.